Carmelita Marcantoni
Overview
Explore the profile of Carmelita Marcantoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
827
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lo Cicero L, Lentini P, Sessa C, Castellino N, DAnca A, Torrisi I, et al.
Cardiorenal Med
. 2024 Dec;
15(1):29-40.
PMID: 39631378
Background: Patients with chronic kidney disease (CKD) have an increased cardiovascular (CV) risk. The lower the glomerular filtration rate, the higher the CV risk. Summary: Current data suggest that several...
2.
Giunta R, Gervasi L, Torrisi I, Aliotta R, Marcantoni C
J Nephrol
. 2024 May;
37(8):2371-2374.
PMID: 38709446
No abstract available.
3.
Zanoli L, Marcantoni C, Santoro D
Angiology
. 2024 Mar;
:33197241239690.
PMID: 38487869
No abstract available.
4.
Di Pietro S, Torcitto A, Marcantoni C, Giordano G, Campisi C, Failla G, et al.
Diagnostics (Basel)
. 2023 Dec;
13(23).
PMID: 38066815
Autosomal dominant polycystic renal disease (ADPKD) is the most frequent kidney inheritable disease, characterized by the presence of numerous bilateral renal cysts, causing a progressive increase in total kidney volume...
5.
Kiryluk K, Sanchez-Rodriguez E, Zhou X, Zanoni F, Liu L, Mladkova N, et al.
Nat Genet
. 2023 Jun;
55(7):1091-1105.
PMID: 37337107
IgA nephropathy (IgAN) is a progressive form of kidney disease defined by glomerular deposition of IgA. Here we performed a genome-wide association study of 10,146 kidney-biopsy-diagnosed IgAN cases and 28,751...
6.
Duminuco A, Cupri A, Milone G, Marcantoni C, Leotta S, Esposito B, et al.
Transpl Immunol
. 2022 Sep;
75:101705.
PMID: 36055435
Treatment of neoplastic diseases resistant to conventional chemotherapies is still an open challenge. The increasing development of chemical molecules or monoclonal antibodies able to recognize precise molecular targets of cancer...
7.
Orlacchio A, Guastoni C, Beretta G, Cosmai L, Galluzzo M, Gori S, et al.
Radiol Med
. 2022 Mar;
127(5):534-542.
PMID: 35303246
The increasing number of examinations and interventional radiological procedures that require the administration of contrast medium (CM) in patients at risk for advanced age and/or comorbidities highlights the problem of...
8.
Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, et al.
J Am Soc Nephrol
. 2021 Mar;
32(4):972-982.
PMID: 33649098
Background: A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for membranous nephropathy. Compared with this regimen, rituximab therapy might have a more favorable safety profile, but a head-to-head comparison is...
9.
Sessa C, Castellino P, Battaglia G, Fatuzzo P, Gaudio A, Granata A, et al.
G Ital Nefrol
. 2020 Dec;
37(6).
PMID: 33295707
Chronic kidney disease is associated with an increased cardiovascular risk. Several uremic toxins are also vascular toxins and may contribute to the increase of the cardiovascular risk through the development...
10.
Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, et al.
Nat Commun
. 2020 Apr;
11(1):1600.
PMID: 32231244
Membranous Nephropathy (MN) is a rare autoimmune cause of kidney failure. Here we report a genome-wide association study (GWAS) for primary MN in 3,782 cases and 9,038 controls of East...